EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis

Chetan B Mukhtyar, Elena Nikiphorou, Alice Bartoletti, Mrinalini Dey, Georgina Ducker, Durga P Misra, Sara Monti, Paul Studenic, Alvise Berti, Daniel Blockmans, Elisabeth Brouwer, Frank Buttgereit und 16 weitere

Annals of the Rheumatic Diseases · 2026-07

DOI: 10.1016/j.ard.2026.06.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-07. Verfasst von Chetan B Mukhtyar und 27 weiteren Autor:innen. Beteiligte Einrichtung: Vasculitis Unit, Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK. Electronic address: chetan.m…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Alliance of Associations for Rheumatology.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to update the European Alliance of Associations for Rheumatology (EULAR) recommendations for management of polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and Takayasu arteritis (TAK). METHODS: Following EULAR standard operating procedures, systematic literature reviews identified data published since the previous versions for PMR (2015) and for GCA/TAK (2018). An international task force discussed the evidence, and following a structured voting process, created overarching principles, recommendations, and quality indicators. RESULTS: The task force agreed on 4 overarching principles, 12 recommendations, and 2 quality indicators. All patients with suspected PMR, GCA, or TAK should be referred for specialist assessment and those with suspected GCA within 24 hours. In patients with a strong clinical suspicion of GCA, treatment with glucocorticoids (GCs) should be commenced without delay, while waiting for the results of confirmatory investigations. For most patients with suspected PMR or TAK, treatment with GC can be delayed until the diagnosis is confirmed. For induction of remission, GC should be initiated at a dose of 15 to 25 mg/day prednisone-equivalent for PMR and 40 to 60 mg for GCA or TAK. Guidance on GC tapering is provided. Adjunctive therapy is recommended for selected patients with PMR or GCA using either interleukin (IL)-6 receptor inhibitors for PMR and GCA or upadacitinib for GCA. Methotrexate may be an alternative. GC-sparing agents should be given in combination with GC to all patients with TAK. All overarching principles and recommendations met with high levels of agreement. CONCLUSIONS: Updated guidance on management of PMR and large vessel vasculitis is provided in a single set of practical recommendations and algorithms.

Autor:innen und Institutionen

  • Vasculitis Unit, Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK. Electronic address: chetan.mukhtyar@nnuh.nhs.uk.
  • Centre for Rheumatic Diseases, Faculty of Life Sciences & Medicine, School of Immunology & Microbial Sciences, King's College London, London, UK; Centre for Education, Faculty of Life Sciences & Medicine, King's College…
  • Vasculitis Unit, Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK; Department of Rheumatology, ASST Gaetano Pini CTO, Milan, Italy.
  • Centre for Rheumatic Diseases, Faculty of Life Sciences & Medicine, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Vasculitis Unit, Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
  • Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India.

Förderung

  • European Alliance of Associations for Rheumatology

Zitieren

APA

Mukhtyar, C. B., Nikiphorou, E., Bartoletti, A., Dey, M., Ducker, G., Misra, D. P., Monti, S., Studenic, P., Berti, A., Blockmans, D., Brouwer, E., Buttgereit, F., Cannings, K., Cid, M. C., Conway, R., Christ, L., Dejaco, C., Keller, K. K., Kingham, L., …, & Hellmich, B. (2026). 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.06.009

Vancouver

Mukhtyar CB, Nikiphorou E, Bartoletti A, Dey M, Ducker G, Misra DP, et al. 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2026.06.009

BibTeX
@article{Mukhtyar2026,
  author = {Mukhtyar, Chetan B and Nikiphorou, Elena and Bartoletti, Alice and Dey, Mrinalini and Ducker, Georgina and Misra, Durga P and Monti, Sara and Studenic, Paul and Berti, Alvise and Blockmans, Daniel and Brouwer, Elisabeth and Buttgereit, Frank and Cannings, Kathleen and Cid, Maria C and Conway, Richard and Christ, Lisa and Dejaco, Christian and Keller, Kresten K and Kingham, Lisa and Merkel, Peter A and Mohammad, Aladdin J and Mollan, Susan P and Nielsen, Berit D and Ponte, Cristina and Saadoun, David and Schmidt, Wolfgang A and Warrington, Kenneth J and Hellmich, Bernhard},
  title = {2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2026.06.009}
}
Kostenlos starten →